Jan 15, 2020 / 09:30PM GMT
Richard Vosser - JP Morgan Chase & Co, Research Division - Senior Analyst
Good afternoon. Welcome to the Ipsen presentation at the JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan, and it's my great pleasure to introduce the CEO and CFO, Aymeric Le Chatelier, from Ipsen.
Before I hand over to Aymeric, the breakout session following this presentation is in the Georgian Room, which is just around the corner. Aymeric, welcome to the conference.
Aymeric Le Chatelier - Ipsen S.A. - Executive VP, Interim CEO & CFO
Okay, thank you. Thank you very much, Richard. I'm very pleased to be with you this afternoon and to provide you with an update on Ipsen.
So clearly -- before the safe harbor, so clearly, at Ipsen, we continue to deliver on our vision of being a leading global biopharma focused on innovation and specialty care. And as you see, we are growing our 2 businesses, I mean, our specialty care business accounting for almost 90% of our sales, focusing on 3 therapeutic area, being oncology, more than 70
Ipsen SA at JPMorgan Healthcare Conference Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers